Literature DB >> 20647308

p27Kip1 mediates addiction of ovarian cancer cells to MYCC (c-MYC) and their dependence on MYC paralogs.

Tulsiram Prathapam1, Alexey Aleshin, Yinghui Guan, Joe W Gray, G Steven Martin.   

Abstract

The MYCC (c-MYC) gene is amplified in 30-60% of human ovarian cancers. We assessed the functional significance of MYCC amplification by siRNA inhibition of MYCC or MYC paralogs in a panel of ovarian cancer cell lines expressing varying levels of MYCC. Inactivation of MYCC inhibited cell proliferation and induced replicative senescence only in lines with amplified MYCC, indicating that these cells are addicted to continued MYCC overexpression. In contrast, siRNA knockdown of all three MYC isoforms inhibited proliferation of MYCC non-amplified ovarian cancer cells without inducing replicative senescence, and did not inhibit the proliferation of telomerase-immortalized ovarian surface epithelial cells. The arrest induced by MYCC knockdown was accompanied by an increase in the level of the Cdk inhibitor p27(Kip1) and a decrease in cyclin A expression and Cdk2 activity, and could be reversed by RNAi knockdown of p27(Kip1) or Rb, or by overexpression of cyclin A/Cdk2. The arrest induced by knockdown of all three MYC isoforms could similarly be reversed by p27(Kip1) knockdown. Our findings indicate that the addiction of MYCC-amplified ovarian cancer cells to MYCC differs from the dependence of MYCC non-amplified cancer cells on MYC paralogs, but both are mediated, at least in part, by p27(Kip1). They also suggest that growth of ovarian cancers may be blocked by inhibition of MYCC or MYC paralogs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20647308      PMCID: PMC2952255          DOI: 10.1074/jbc.M110.151902

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle.

Authors:  H Wang; S Mannava; V Grachtchouk; D Zhuang; M S Soengas; A V Gudkov; E V Prochownik; M A Nikiforov
Journal:  Oncogene       Date:  2007-10-01       Impact factor: 9.867

Review 2.  Facilitating replication under stress: an oncogenic function of MYC?

Authors:  Steffi Herold; Barbara Herkert; Martin Eilers
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 3.  Reflecting on 25 years with MYC.

Authors:  Natalie Meyer; Linda Z Penn
Journal:  Nat Rev Cancer       Date:  2008-12       Impact factor: 60.716

4.  Genomic and proteomic analysis reveals a threshold level of MYC required for tumor maintenance.

Authors:  Catherine M Shachaf; Andrew J Gentles; Sailaja Elchuri; Debashis Sahoo; Yoav Soen; Orr Sharpe; Omar D Perez; Maria Chang; Dennis Mitchel; William H Robinson; David Dill; Garry P Nolan; Sylvia K Plevritis; Dean W Felsher
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

Review 5.  Oncogene addiction.

Authors:  I Bernard Weinstein; Andrew Joe
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Repression of transcription of the p27(Kip1) cyclin-dependent kinase inhibitor gene by c-Myc.

Authors:  W Yang; J Shen; M Wu; M Arsura; M FitzGerald; Z Suldan; D W Kim; C S Hofmann; S Pianetti; R Romieu-Mourez; L P Freedman; G E Sonenshein
Journal:  Oncogene       Date:  2001-03-29       Impact factor: 9.867

Review 7.  The Pezcoller lecture: cancer cell cycles revisited.

Authors:  C J Sherr
Journal:  Cancer Res       Date:  2000-07-15       Impact factor: 12.701

Review 8.  Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?

Authors:  Dean W Felsher
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Authors:  D Zhuang; S Mannava; V Grachtchouk; W-H Tang; S Patil; J A Wawrzyniak; A E Berman; T J Giordano; E V Prochownik; M S Soengas; M A Nikiforov
Journal:  Oncogene       Date:  2008-08-04       Impact factor: 9.867

10.  Modelling Myc inhibition as a cancer therapy.

Authors:  Laura Soucek; Jonathan Whitfield; Carla P Martins; Andrew J Finch; Daniel J Murphy; Nicole M Sodir; Anthony N Karnezis; Lamorna Brown Swigart; Sergio Nasi; Gerard I Evan
Journal:  Nature       Date:  2008-08-17       Impact factor: 49.962

View more
  14 in total

1.  Targeting c-MYC in Platinum-Resistant Ovarian Cancer.

Authors:  Jeyshka M Reyes-González; Guillermo N Armaiz-Peña; Lingegowda S Mangala; Fatma Valiyeva; Cristina Ivan; Sunila Pradeep; Ileabett M Echevarría-Vargas; Adrian Rivera-Reyes; Anil K Sood; Pablo E Vivas-Mejía
Journal:  Mol Cancer Ther       Date:  2015-07-30       Impact factor: 6.261

2.  Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma.

Authors:  Amir A Jazaeri; Jennifer L Bryant; Hong Park; Hui Li; Neetu Dahiya; Mark H Stoler; James Stuart Ferriss; Anindya Dutta
Journal:  Neoplasia       Date:  2011-10       Impact factor: 5.715

3.  Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers.

Authors:  Yao-An Shen; Jiaxin Hong; Ryoichi Asaka; Shiho Asaka; Fang-Chi Hsu; Yohan Suryo Rahmanto; Jin-Gyoung Jung; Yu-Wei Chen; Ting-Tai Yen; Alicja Tomaszewski; Cissy Zhang; Nabeel Attarwala; Angelo M DeMarzo; Ben Davidson; Chi-Mu Chuang; Xi Chen; Stephanie Gaillard; Anne Le; Ie-Ming Shih; Tian-Li Wang
Journal:  Cancer Res       Date:  2020-08-28       Impact factor: 12.701

4.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.

Authors:  Jing Sun; Xin Cai; Mingo Mh Yung; Wei Zhou; Jing Li; Yi Zhang; Zhuqing Li; Stephanie S Liu; Annie N Y Cheung; Hextan Y S Ngan; Yiliang Li; Zhijun Dai; Yan Kai; Alexandros Tzatsos; Weiqun Peng; David W Chan; Wenge Zhu
Journal:  Oncogene       Date:  2018-08-30       Impact factor: 9.867

5.  An RGDKGE-Containing Cryptic Collagen Fragment Regulates Phosphorylation of Large Tumor Suppressor Kinase-1 and Controls Ovarian Tumor Growth by a Yes-Associated Protein-Dependent Mechanism.

Authors:  XiangHua Han; Jennifer M Caron; Christine W Lary; Pradeep Sathyanarayana; Calvin Vary; Peter C Brooks
Journal:  Am J Pathol       Date:  2020-12-08       Impact factor: 4.307

6.  Overexpression of KLF4 promotes cell senescence through microRNA-203-survivin-p21 pathway.

Authors:  Qing Xu; Mei Liu; Ju Zhang; Liyan Xue; Guo Zhang; Chenfei Hu; Zaozao Wang; Shun He; Lechuang Chen; Kai Ma; Xianghe Liu; Yahui Zhao; Ning Lv; Shufang Liang; Hongxia Zhu; Ningzhi Xu
Journal:  Oncotarget       Date:  2016-09-13

7.  Clinical Importance of Myc Family Oncogene Aberrations in Epithelial Ovarian Cancer.

Authors:  MoonSun Jung; Amanda J Russell; Catherine Kennedy; Andrew J Gifford; Kylie-Ann Mallitt; Siva Sivarajasingam; David D Bowtell; Anna DeFazio; Michelle Haber; Murray D Norris; Michelle J Henderson
Journal:  JNCI Cancer Spectr       Date:  2018-11-16

8.  Bioinformatic analysis reveals MIR502 as a potential tumour suppressor in ovarian cancer.

Authors:  Yan Li; Qi Wang; Ning Ning; Fanglan Tang; Yan Wang
Journal:  J Ovarian Res       Date:  2020-07-13       Impact factor: 4.234

9.  Altered glutamine metabolism in platinum resistant ovarian cancer.

Authors:  Chantelle D Hudson; Alyssa Savadelis; Anil Belur Nagaraj; Peronne Joseph; Stefanie Avril; Analisa DiFeo; Norbert Avril
Journal:  Oncotarget       Date:  2016-07-05

10.  Time-Dependent Effects of POT1 Knockdown on Proliferation, Tumorigenicity, and HDACi Response of SK-OV3 Ovarian Cancer Cells.

Authors:  Hua Zhou; Abdul Mondal; Aleksandra Dakic; Lama Alhawas; Xuefeng Liu; Zhixu He
Journal:  Biomed Res Int       Date:  2018-02-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.